Publications for Henrik Green
Co-author map based on ISI articles 2007-
Publications mentioned in social media 6 times*
Journal Articles
Liza Ljungberg, Karin Persson, Andreas Eriksson, Henrik Green and Per Whiss
Effects of nicotine, its metabolites and tobacco extracts on human platelet function in vitro
Toxicology in Vitro, 2013, 27(2), 932-938.
Fulltext  |
Troels K Bergmann, Werner Vach, Soren Feddersen, Lise Eckhoff, Henrik Green, Jorn Herrstedt and Kim Brosen
Letter: GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients
Acta Oncologica, 2013, 52(4), 871-U231.
|
Martin N Fransson, Jan Brugard, Peter Aronsson and Henrik Green
Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics
European Journal of Pharmaceutical Sciences, 2012, 47(4), 759-767.
Fulltext |
Johanna Hasmats, Ilya Kupershmidt, Cristina Rodriguez-Antona, Qiaojuan Jane Su, Muhammad Suleman Khan, Carlos Jara, Xabier Mielgo, Joakim Lundeberg and Henrik Green
Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues
Gene, 2012, 506(1), 62-68.
|
Luis J Leandro-Garcia, Susanna Leskelae, Carlos Jara, Henrik Green, Elisabeth Avall-Lundqvist, Heather E Wheeler, M Eileen Dolan, Lucia Inglada-Perez, Agnieszka Maliszewska, Aguirre A de Cubas, Inaki Comino-Mendez, Veronika Mancikova, Alberto Cascon, Mercedes Robledo and Cristina Rodriguez-Antona
Regulatory Polymorphisms in beta-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Clinical Cancer Research, 2012, 18(16), 4441-4448.
Web of Science® Times Cited: 4 |
Henrik Green, Ingrid Jakobsen Falk, Kourosh Lotfi, E Paul, M Hermansson, R Rosenquist, C Paul and H Nahi
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype
The Pharmacogenomics Journal, 2012, 12(2), 111-118.
Fulltext Web of Science® Times Cited: 1 |
Troels K Bergmann, Charlotte Brasch-Andersen, Henrik Green, Mansoor R Mirza, Kristin Skougaard, Jessica Wihl, Nina Keldsen, Per Damkier, Curt Peterson, Werner Vach and Kim Brosen
Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer
Basic & Clinical Pharmacology & Toxicology, 2012, 110(2), 199-204.
|
Ingrid Jakobsen Falk, Muhammad Suleman Khan, Lena Thunell, Hareth Nahi and Henrik Green
Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma
Journal of Cancer Therapy, 2012, 3(1), 20-27.
|
Tove Sivik, Svante Vikingsson, Henrik Gréen and Agneta Jansson
Expression Patterns of 17β-Hydroxysteroid Dehydrogenase 14 in Human Tissues
Hormone and Metabolic Research, 2012, 44(13), 949-956.
|
Emelie Djerf, Cecilia Trinks, Henrik Green, Avni Abdiu, Anna-Lotta Hallbeck, Olle Stål and Thomas Walz
The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo
Biochemical and Biophysical Research Communications - BBRC, 2011, 414(3), 563-568.
|
Henrik Green, Olle Stål, K Bachmeier, L M Bäcklund, L Carlsson, J Hansen, M Lagerlund, B Norberg, A Franzén, A Åleskog and Annika Malmström
Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified
Cancer Letters, 2011, 313(2), 145-153.
Fulltext Web of Science® Times Cited: 1 |
Mette M H Christensen, Charlotte Brasch-Andersen, Henrik Green, Flemming Nielsen, Per Damkier, Henning Beck-Nielsen and Kim Brosen
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
Pharmacogenetics & Genomics, 2011, 21(12), 837-850.
Web of Science® Times Cited: 9 |
Amanda Nordigården, Jenny Zetterblad, Cecilia Trinks, Henrik Green, Pernilla Eliasson, Pia Druid, Kourosh Lotfi, Lars Ronnstrand, Thomas Walz and Jan-Ingvar Jönsson
Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice
British Journal of Haematology, 2011, 155(2), 198-208.
Fulltext Web of Science® Times Cited: 1 |
Henrik Green, Muhammad Suleman Khan, Ingrid Jakobsen Falk, Elisabeth Avall-Lundqvist and Curt Peterson
Impact of CYP3A5(*)3 and CYP2C8-HapC on Paclitaxel/Carboplatin-Induced Myelosuppression in Patients with Ovarian Cancer
Journal of Pharmaceutical Sciences, 2011, 100(10), 4205-4209.
Fulltext Web of Science® Times Cited: 2 |
Anna Gréen, Bettina Sarg, Henrik Green, Anita Lönn, Herbert H Lindner and Ingemar Rundquist
Histone H1 interphase phosphorylation becomes largely established in G(1) or early S phase and differs in G(1) between T-lymphoblastoid cells and normal T cells
EPIGENETICS and CHROMATIN, 2011, 4(15), .
Fulltext Web of Science® Times Cited: 1 |
Cecilia Trinks, Emelie A. Severinsson, Birgitta Holmlund, Anna Gréen, Henrik Green, Jan-Ingvar Jönsson, Anna-Lotta Hallbeck and Thomas Walz
The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells
Biochemical and Biophysical Research Communications - BBRC, 2011, 410(3), 422-427.
Web of Science® Times Cited: 1 |
Troels K. Bergmann, Henrik Green, Charlotte Brasch-Andersen, Mansoor R. Mirza, Jorn Herrstedt, Berit Holund, Andreas du Bois, Per Damkier, Werner Vach, Kim Brosen and Curt Peterson
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
European Journal of Clinical Pharmacology, 2011, 67(7), 693-700.
Web of Science® Times Cited: 8 |
Cristina Rodríguez-Antona and Henrik Gréen
Editorial: Microtubule-targeting drugs and personalization of cancer treatment.
Pharmacogenomics (London), 2011, 12(4), 449-51.
|
T K Bergmann, C Brasch-Andersen, Henrik Green, M Mirza, R S Pedersen, F Nielsen, K Skougaard, J Wihl, N Keldsen, P Damkier, L E Friberg, Curt Peterson, W Vach, M O Karlsson and K Brosen
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer
PHARMACOGENOMICS JOURNAL, 2011, 11(2), 113-120.
Fulltext Web of Science® Times Cited: 18 |
Martin N Fransson, Henrik Green, Jan-Eric Litton and Lena E Friberg
Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model
DRUG METABOLISM AND DISPOSITION, 2011, 39(2), 247-255.
Web of Science® Times Cited: 6 |
Tove Sivik, Svante Vikingsson, Henrik Greén and Agneta Jansson
A validated and rapid high-performance liquidchromatography method for the quantification ofconversion of radio-labelled sex steroids
Hormone Molecular Biology and Clinical Investigation, 2010, 3(1), 375-381.
|
Henrik Green, Karin Skoglund, Franz Rommel, Rajaa A Mirghani and Kourosh Lotfi
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66(4), 383-386.
Fulltext Web of Science® Times Cited: 14 |
Henrik Green, Peter Söderkvist, Per Rosenberg, Rajaa A Mirghani, Per Rymark, Elisabeth Avall Lundqvist and Curt Peterson
Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer
Basic and clinical pharmacology and toxicology, 2009, 104(2), 130-137.
Fulltext Web of Science® Times Cited: 27 |
Henrik Green
Pharmacogenomics of importance for paclitaxel chemotherapy
Pharmacogenomics (London), 2008, 9(6), 671-674.
Fulltext Web of Science® Times Cited: 7 |
Henrik Green, Peter Söderkvist, Per Rosenberg, Grörgy Horvath and Curt Peterson
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel
Journal of Pharmaceutical Sciences, 2008, 97(6), 2045-2048.
Fulltext Web of Science® Times Cited: 20 |
Martin Fransson and Henrik Gréen
Comparison of two types of population pharmacokinetic model structures of paclitaxel
European Journal of Pharmaceutical Sciences, 2008, 33(2), 128-137.
Web of Science® Times Cited: 3 |
Henrik Green, Peter Söderkvist, Per Rosenberg, Rajaa A. Mirghani, Per Rymark, Elisabeth Åvall-Lundqvist and Curt Peterson
Pharmacogenetics of Paclitaxel in the Treatment of Ovarian Cancer – a Pilot Study in Preparation of Individualized Chemotherapy
Clinical Cancer Research, 2007, , .
|
Henrik Green, Peter Söderkvist, Per Rosenberg, Horvath György and Curt Peterson
Letters to the Editor: ABCB1 2677>T/A Genotype and paclitaxel pharmacogenetics in ovarian cancer - Response
Clinical Cancer Research, 2006, 12(13), 4127-4129.
|
Henrik Green, Karin Vretenbrant (Öberg), Björn Norlander and Curt Peterson
Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface
Rapid Communications in Mass Spectrometry, 2006, 20(14), 2183-2189.
Fulltext Web of Science® Times Cited: 11 |
Henrik Green, Peter Söderkvist, Per Rosenberg, György Horvath and Curt Peterson
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue – G2677T/A correlates with response to paclitaxel chemotherapy
Clinical Cancer Research, 2006, 12(3 pt 1), 854-859.
Fulltext Web of Science® Times Cited: 81 |
Henrik Green, Per Rosenberg, Peter Söderkvist, György Horvath and Curt Peterson
β-tubulin mutations in ovarian cancer using single strand conformation analysis – risk of false positive results from paraffin embedded tissues
Cancer Letters, 2006, 236(1), 148-154.
Fulltext Web of Science® Times Cited: 5 |
Henrik Green, Kourosh Lotfi, Anna Lena Zackrisson and Curt Peterson
Spontaneous Reversal of P-Glycoprotein Expression in Multidrug Resistant Cell Lines
Pharmacology and Toxicology, 2003, 93(6), 297-304.
Fulltext Web of Science® Times Cited: 5 |
Samuel Svensson, Sofi Lindgren, Wendy Powell and Henrik Green
Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells
Pigment Cell Research, 2003, 16(4), 351-354.
Web of Science® Times Cited: 10 |
Conference Articles
Karin Skoglund, Samuel Boiso Moreno, Jan-Ingvar Jönsson and Henrik Green
Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells in BLOOD, vol 118, issue 21, pp 1491-1491
BLOOD, 2011.
|
Christer Paul, Henrik Green, Ingrid Jakobsen Falk, Kourosh Lotfi, Esbjorn Paul, Monika Hermansson, Richard Rosenquist, Kerstin Jonsson-Videsater and Hareth Nahi
Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML in BLOOD, vol 114, issue 22, pp 1038-1039
BLOOD, 2009.
|
T K Bergmann, Henrik Green, M O Karlsson, L Friberg, F Nielsen, C Brasch-Andersen and K Brosen
Impact of sequence variants in CYP2C8 on paclitaxel clearance in ovarian cancer patients in EJC SUPPLEMENTS, vol 7, issue 2, pp 92-92
EJC SUPPLEMENTS, 2009.
|
E. Paul, Kourosh Lotfi, I. Jakobsen Falk, R. Rosenquist, C. Paul, H. Nahi and Henrik Green
ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN DE NOVO AML WITH NORMAL KARYOTYPE - IMPLICATIONS ON DRUG RESISTANCE AND SURVIVAL
in HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol 94, 2009.
|
Henrik Gréen, Karin Vretenbrandt, Björn Norlander and Curt Peterson
Measurement of Paclitaxel and its metabolites in Human Plasma Using a Liquid Chromatography - Ion Trap Mass Spectrometer with a SSI interface
Mass Spectrometry of Small Molecular Drugs, 2008.
|
Peter Fritzson, Erik Ulfhielm, Ales Belic, Martin Fransson and Henrik Green
Biochemical Mathematical Modeling with Modelica and the BioChem Library
Aplimat 2007,2007, 2007.
|
Henrik Green, Karin Skoglund, Franz Rommel, Leif Bertilsson and Kourosh Lotfi
Influence of CYP3A4 activity on imatinib response in paitents with chronic myeloid leukemia
11th congress of the European Heamtology Association,2006, 2006.
|
Henrik Gréen, Cecilia Runnqvist, Julia Bak, Peter Söderqvist, Per Rosenberg and Curt Peterson
Strategies for individualization of Taxol (paclitaxel) treatment of ovarian cancer
Proceedings of the American Association for Cancer Research,2002, 2002.
|
Wendy Powell, Henrik Green and Samuel Svensson
A new method for screening the melanin binding ability of different antineoplastic agents.
Pigment cell research,2001, 2001.
|
Henrik Gréen, Malin Lindqvist Appell, Anna Lena Zackrisson, Gunnar Juliusson and Curt Peterson
P-gp and mdr-1 mRNA in leukemic cells fromAML patients during chemotheraphy.
Proceedings of the American Association for Cancer Research,2001, 2001.
|
Ph.D. Theses
* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.
Ph.D., Lic. Theses
